Biotechnology
Prilenia Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders. The company's lead product candidate, pridopidine, is a Sigma-1 receptor agonist that holds Orphan Drug Designation in both Huntington's disease and amyotrophic lateral sclerosis (ALS) in the U.S. and EU, and has received Fast Track designation from the FDA for HD treatment. Prilenia is conducting global Phase 3 clinical trials in both HD and ALS, with pridopidine positioned as a potential pivotal treatment to address disease progression. Beyond HD and ALS, the company believes pridopidine's novel mechanism of action has potential in numerous other neurodegenerative and neurodevelopmental conditions.
Beta · Sourced from candidate reports
Be the first to share your experience with Prilenia.
Your reply helps other candidates know what to expect.
